Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Received: 4 February 2019
Accepted: 17 April 2019
First Online: 30 April 2019
Ethics approval and consent to participate
: Not applicable
: Not applicable
: S Auvin has served as a speaker and consultant for Advicenne Pharma, Eisai, GW Pharmaceuticals, Novartis Pharmaceuticals, Nutricia, UCB Pharma, Ultragenyx, Vitaflo, and Zogenix.JJ Bissler has received research grants (to his institution) from Novartis, has served as a consultant for and participated in advisory boards for Novartis, and has received travel honoraria from Novartis.V Cottin has served as a consultant and speaker for and received travel honoraria from Actelion Pharmaceuticals, Boehringer Ingelheim, and Roche Pharmaceuticals, has received research grants (to his institution) from Roche and Sanofi, served as a consultant for Bayer / MSD, Novartis, and Galapagos, and served as a committee member for Gilead Sciences, Promedior, and Celgene.A Fujimoto has nothing to disclose.GFL Hofbauer has received speaker’s fees and consulting honoraria from Novartis.AC Jansen has received honoraria from Novartis and has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in, or financial conflict with, the subject matter of material discussed in the manuscript.S Jóźwiak was partly financed by the European Community’s Seventh Framework Programme (FP7/2007–2013; EPISTOP, grant agreement no. 602391), the Polish Ministerial funds for science (years 2013–2019) for the implementation of international co-financed project and the grant EPIMARKER of the Polish National Center for Research and Development No STRATEGMED3/306306/4/2016.L Kerecuk has served as a speaker for and received travel honoraria from Novartis, and as a consultant for Roche Pharmaceuticals.JC Kingswood has received research grants (to his institution) from Novartis and has served as a consultant for Novartis.R Moavero has participated in advisory boards for Novartis and has research that was partly funded by EPISTOP.R Torra has nothing to disclose.V Villanueva has participated in advisory boards and symposia for Eisai, UCB Pharma, BIAL, Esteve, Novartis, and GW Pharma.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.